Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Neoplasms, Germ Cell and Embryonal » Neuroectodermal Tumors » Neoplasms, Neuroepithelial » Glioma
Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Neoplasms, Glandular and Epithelial » Neoplasms, Neuroepithelial » Glioma
Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Neoplasms, Nerve Tissue » Neuroectodermal Tumors » Neoplasms, Neuroepithelial » Glioma
Description
Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21) MeSH
Hierarchy View
Subtype Terms (8)
Astrocytoma
208 drugs (102 approved, 106 experimental)
Diffuse Intrinsic Pontine Glioma
86 drugs (39 approved, 47 experimental)
Ependymoma
121 drugs (73 approved, 48 experimental)
Ganglioglioma
6 drugs (5 approved, 1 experimental)
Gliosarcoma
163 drugs (83 approved, 80 experimental)
Medulloblastoma
145 drugs (83 approved, 62 experimental)
Oligodendroglioma
129 drugs (69 approved, 60 experimental)
Optic Nerve Glioma
11 drugs (9 approved, 2 experimental)
Approved Indicated Drugs (7)
Phase 4 Indicated Drugs (19)
Phase 3 Indicated Drugs (16)
Phase 1 Indicated Drugs (125)
Anti-thymocyte Globulin (Rabbit) (Thymoglobulin)
autologous cd19car-cd28-cd3zeta-egfrt-expressing tn/mem-enriched t-lymphocytes
autologous dendritic cells loaded with autologous tumor lysate
autologous hematopoietic stem cells
autologous natural killer cells
cd19car-cd28-cd3zeta-egfrt-expressing tcm-enriched t-lymphocytes
cd28-cd3zeta-cd19t-expressing car t cells
neural stem cells-expressing crad-s-pk7
neural stem cells loaded with an oncolytic adenovirus
Other Experimental Indicated Drugs (25)
Organization Involved with Phase 4 Indications (8)
Organization Involved with Phase 3 Indications (39)
Ann & Robert H Lurie Children's Hospital of Chicago
Case Western Reserve University
Chinese Academy of Medical Sciences
Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany
Organization Involved with Phase 2 Indications (245)
Assistance Publique - Hôpitaux de Paris
BioMimetix Pharmaceutical, Inc.
Biotech Pharmaceutical Co., Ltd.
Brain Tumor Trials Collaborative
Canadian Paediatric Brain Tumour Program
Centro de Immunologia Molecular, Cuba
Children's Cancer and Leukaemia Group
Children's Hospital Los Angeles
Children's National Medical Center
Children's National Research Institute
Cook Children's Medical Center
Den-Mei Brain Tumor Education Foundation, Taichung, Taiwan
Developmental Therapeutics Consortium
Dr. Negrin University Hospital
ECOG-ACRIN Cancer Research Group
Florida Cancer Specialists, Sarasota
Fundación DISA, Canary Islands, Spain
Grupo de Investigación Clínica en Oncología Radioterapia
Hackensack University Medical Center
Herbert Irving Comprehensive Cancer Center
Huazhong University of Science and Technology
Icahn School of Medicine at Mount Sinai
Innovative Therapies For Children with Cancer Consortium
Long Island Neuro-Oncology Associates
Medical University of South Carolina
MultiCare Health System Research Institute
National Cancer Institute, France
National Institute of Neurological Disorders and Stroke (NINDS)
National Institutes of Health (NIH)
Online Collaborative Oncology Group
Ontario Cancer Research Network
Oregon Health and Science University
Pediatric Brain Tumor Consortium
Pediatric Oncology Experimental Therapeutics Investigation Consortium
Pediatric Oncology Group of Ontario
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Royal Marsden Hospital NHS Trust
San Diego Pacific Oncology & Hematology Associates
Spanish National Health System
The Pacific Pediatric Neuro-Oncology Consortium
The Pediatric Low Grade Astrocytoma Foundation
The University of Texas, Dallas
Triphase Research and Development Corporation
Universidad Autonoma de Barcelona
University of Alabama, Birmingham
University of California, Davis
University of California, San Diego
University of North Carolina at Chapel Hill
University of Southern California
University of Southern Denmark
University of Texas, San Antonio
Virginia Commonwealth University
Washington University in St. Louis
Organization Involved with Phase 1 Indications (88)
American Board for Transplant Certification
American Lebanese Syrian Associated Charities
Annias Immunotherapeutics, Inc.
Beijing Pearl Biotechnology Limited Liability Company
Cancer and Leukemia Group B (CALGB)
Cannonball Kids' Cancer Foundation
Center Trials & Treatment Inc.
City of Hope National Medical Center
Hebei Senlang Biotechnology Inc., Ltd.
Institut de Cancerologie de l'Ouest Paul Papin
National Pediatric Cancer Foundation
Neuro-Oncology Working Group of the German Cancer Society
Pediatric Brain Tumor Foundation
Organization Involved with Other Experimental Indications (13)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
